Press Releases

KemPharm® is a rare disease therapeutics company focused on the discovery, development and commercialization of novel treatments for rare CNS and neurodegenerative diseases, lysosomal storage disorders and related treatment areas.

Press Releases

News Releases

Date Title and Summary
Toggle Summary KemPharm Enhances Senior Management Team
Daniel Gallo , Ph.D., Appointed Senior Vice President of Medical Affairs and Advocacy Abbi Maher , J.D., Named Vice President of Legal Affairs CELEBRATION, Fla. , Jan. 31, 2023 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NasdaqGS: KMPH) ( KemPharm , or the Company), a rare disease therapeutics company
Toggle Summary KemPharm Issues Letter to Shareholders
CELEBRATION, Fla. , Jan. 24, 2023 (GLOBE NEWSWIRE) -- KemPharm , Inc. (NasdaqGS: KMPH) ( KemPharm , or the Company), a rare disease therapeutics company focused on the development of treatments for rare central nervous system (CNS) disorders, neurodegenerative diseases, lysosomal storage disorders
Toggle Summary KemPharm Partners with the Hypersomnia Foundation to Support Sleep Disorder Research and Advocacy
KemPharm advancing multicenter Phase 2 clinical trial investigating the efficacy and safety of KP1077 for the treatment of idiopathic hypersomnia (IH) CELEBRATION, Fla. , Jan. 18, 2023 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NasdaqGS: KMPH) ( KemPharm , or the Company), a rare disease therapeutics
Toggle Summary KemPharm Announces Promotion of Sven Guenther, Ph.D., to Chief Scientific Officer and Christal Mickle, M.A., to Chief Product Development Officer
Expanded roles for Guenther and Mickle support broader evolution into a leading rare disease company CELEBRATION, Fla. , Jan. 11, 2023 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NasdaqGS: KMPH) ( KemPharm , or the Company), a rare disease therapeutics company focused on the development of treatments for
Toggle Summary KemPharm Announces Board and Leadership Changes to Support its Transformation into a Leading Rare Disease Company
Matthew R. Plooster named Chairman of the Board of Directors Richard W. Pascoe appointed Chief Executive Officer Travis C. Mickle , Ph.D. transitions to President Joshua Schafer appointed Chief Commercial Officer and Executive Vice President of Business Development CELEBRATION, Fla. , Jan.
Toggle Summary KemPharm Announces Initiation of Phase 2 Clinical Trial Investigating KP1077 for the Treatment of Idiopathic Hypersomnia (IH)
Trial designed as a multi-center, dose-optimizing, double-blind, placebo-controlled, randomized-withdrawal study to evaluate safety and efficacy of KP1077, as well as to assess the symptoms and severity of “brain fog” Interim efficacy and safety data expected as early as Q3 2023 CELEBRATION, Fla.
Toggle Summary KemPharm Announces Appointment of Christopher Posner as New Independent Director
24-year global pharmaceutical executive and current president and CEO of Cara Therapeutics joins KemPharm’s Board of Directors CELEBRATION, Fla. , Nov. 29, 2022 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NasdaqGS: KMPH) ( KemPharm , or the Company), a biotechnology company focused on the discovery,
Toggle Summary KemPharm Receives FDA Orphan Drug Designation for Serdexmethylphenidate (SDX) for the Treatment of Idiopathic Hypersomnia (IH)
Phase 2 clinical trial investigating KP1077 in patients with IH expected to initiate prior to year-end 2022 CELEBRATION, Fla. , Nov. 18, 2022 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NasdaqGS: KMPH) ( KemPharm , or the Company), a biotechnology company focused on the discovery, development and
Toggle Summary KemPharm Reports Third Quarter 2022 Results
Conference Call and Live Audio Webcast with Slide Presentation Scheduled for Today, November 9, 2022 , at 5:00 p.m. ET Significant activities underway for preparation of the arimoclomol NDA resubmission Advancing key activities to initiate a Phase 2 clinical trial of KP1077 in IH by year-end 2022
Toggle Summary KemPharm to Report Third Quarter 2022 Financial Results
CELEBRATION, Fla. , Nov. 01, 2022 (GLOBE NEWSWIRE) -- KemPharm , Inc. (NasdaqGS: KMPH) ( KemPharm , or the Company), a biotechnology company focused on the discovery, development and commercialization of novel treatments for rare diseases, today announced that the Company will host a conference